Published in

The Primary Care Companion For CNS Disorders

DOI: 10.4088/pcc.12m01368

Links

Tools

Export citation

Search in Google Scholar

Six-Month Open-Label Follow-Up of Risperidone Long-Acting Injection Use in Pediatric Bipolar Disorder

Journal article published in 2013 by Miguel A. Boarati, Yuan-Pang Wang ORCID, Ana Paula Ferreira-Maia, Ana Rosa S. Cavalcanti, Lee Fu-I.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload

Abstract

Background: Recent studies suggest that risperidone long-acting injection (RLAI) may be considered for controlling mood episodes in bipolar disorder patients who have relapsed due to medication nonadherence or failure to respond to standard therapies. Currently, no study has reported the usefulness of RLAI in youths with bipolar disorder. The aim of this study was to evaluate short-term effects of RLAI in the naturalistic treatment of early-onset bipolar disorder and its role in symptomatic remission and adherence to treatment.